Paravertebral extramedullary haemopoiesis associated with pyruvate kinase deficiency
Toxoplasma gondii in the bone marrow after pancreas–kidney transplantation
Testing children for inherited thrombophilia : more questions than answers
Genetic risk factors of thrombosis in the antiphospholipid syndrome
Preclinical activity of 8-chloroadenosine with mantle cell lymphoma : roles of energy depletion and inhibition of DNA and RNA synthesis
Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy
Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800
Multiple isoforms of PAX5 are expressed in both lymphomas and normal B-cells
Monoclonal B-cell lymphocytosis in first-degree relatives of patients with sporadic (non-familial) chronic lymphocytic leukaemia
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3
Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients
Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia – a prospective study of 20 paediatric patients
Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia
A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin-associated iron overload diseases
Genomic mutations associated with mild and severe deficiencies of transcobalamin I (haptocorrin) that cause mildly and severely low serum cobalamin levels
Association studies of erythoid α-spectrin at the tetramerization site
Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro
MicroRNA expression in chronic lymphocytic leukaemia
Biological markers and prognostic scoring systems in chronic lymphocytic leukaemia
Elevation of clonal serum free light chains in patients with HIV-negative primary effusion lymphoma (PEL) and PEL-like lymphoma
Low dose continuous chemotherapy (LD56) : an active treatment with low toxicity for patients with recurrent/refractory lymphoma not eligible for intensive salvage therapy
Corrigendum